(Q54611969)

1 June 2018

title

Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma. (English)

1 reference

1 June 2018

author name string

Steven J O'Day

1

1 reference

1 June 2018

Anna C Pavlick

2

1 reference

1 June 2018

Mark R Albertini

3

1 reference

1 June 2018

Omid Hamid

4

1 reference

1 June 2018

Heidi Schalch

5

1 reference

1 June 2018

Zhihui Lang

6

1 reference

1 June 2018

Jie Ling

7

1 reference

1 June 2018

Marielena Mata

8

1 reference

1 June 2018

Manjula Reddy

9

1 reference

1 June 2018

Brenda Foster

10

1 reference

1 June 2018

publication date

18 February 2011

1 reference

1 June 2018

Investigational New Drugs

published in

1 reference

1 June 2018

volume

30

1 reference

1 June 2018

page(s)

1074-1081

1 reference

1 June 2018

issue

3

1 reference

1 June 2018

https://scigraph.springernature.com/pub.10.1007/s10637-011-9639-z

exact match

0 references

cites work

Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9639-Z

Genetic epidemiology of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9639-Z

Interleukin-2: clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9639-Z

The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9639-Z

CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9639-Z

CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9639-Z

Alphav integrin-targeted immunoconjugates regress established human tumors in xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9639-Z

Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9639-Z

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9639-Z

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21331745

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A)

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21331745

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21331745

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-011-9639-Z

1 reference

1 June 2018

PubMed ID

21331745

1 reference

1 June 2018